Abstract
Ischemia/reperfusion injury is unavoidable during cardiopulmonary bypass surgery because the surgery is conducted during ischemic arrest of the heart. Animal studies have shown that the administration of angiotensin converting enzyme (ACE) inhibitors can protect against lethal arrhythmias, preserve ventricular function, and improve coronary reserve after ischemia/reperfusion. Two factors to consider when using ACE inhibitors are their temperature dependency (because cardiopulmonary bypass surgery is usually done under hypothermic conditions) and their direct effect on the bypass material. In this paper, we review studies of ACE inhibitors and discuss both their temperature dependency and their effect on bypass material, especially on the coating of the circuit tube and artificial lung. Finally, we explore the potential clinical applications of ACE inhibitors in cardiopulmonary bypass surgery, taking into consideration the findings of our own preliminary clinical study.
Keywords: ace inhibitor, cardiopulmonary bypass, heart surgery, biocompatibility, bradykinin, angiotensin, review
Current Enzyme Inhibition
Title: Angiotensin Converting Enzyme Inhibitors and Cardiopulmonary Bypass: Is ACE Inhibitor Safe for Heart Surgery?
Volume: 1 Issue: 3
Author(s): Yasuyuki Shimada and Hideshi Itoh
Affiliation:
Keywords: ace inhibitor, cardiopulmonary bypass, heart surgery, biocompatibility, bradykinin, angiotensin, review
Abstract: Ischemia/reperfusion injury is unavoidable during cardiopulmonary bypass surgery because the surgery is conducted during ischemic arrest of the heart. Animal studies have shown that the administration of angiotensin converting enzyme (ACE) inhibitors can protect against lethal arrhythmias, preserve ventricular function, and improve coronary reserve after ischemia/reperfusion. Two factors to consider when using ACE inhibitors are their temperature dependency (because cardiopulmonary bypass surgery is usually done under hypothermic conditions) and their direct effect on the bypass material. In this paper, we review studies of ACE inhibitors and discuss both their temperature dependency and their effect on bypass material, especially on the coating of the circuit tube and artificial lung. Finally, we explore the potential clinical applications of ACE inhibitors in cardiopulmonary bypass surgery, taking into consideration the findings of our own preliminary clinical study.
Export Options
About this article
Cite this article as:
Shimada Yasuyuki and Itoh Hideshi, Angiotensin Converting Enzyme Inhibitors and Cardiopulmonary Bypass: Is ACE Inhibitor Safe for Heart Surgery?, Current Enzyme Inhibition 2005; 1 (3) . https://dx.doi.org/10.2174/157340805774580475
DOI https://dx.doi.org/10.2174/157340805774580475 |
Print ISSN 1573-4080 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6662 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Anti-Diabetic Drugs GLP-1 Agonists and DPP-4 Inhibitors may Represent
Potential Therapeutic Approaches for COVID-19
Endocrine, Metabolic & Immune Disorders - Drug Targets The Design of Competitive, Small-molecule Inhibitors of Coagulation Factor Xa
Current Topics in Medicinal Chemistry Plasminogen Activator System and Vascular Disease
Current Vascular Pharmacology The Neuroprotective Mechanism of Erythropoietin-TAT Fusion Protein Against Neurodegeneration from Ischemic Brain Injury
CNS & Neurological Disorders - Drug Targets S100A8/A9 as a Pro-inflammatory Cytokine in Obstructive Airway Disease Via the Multi-Ligand Receptor, RAGE
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Potential Therapeutic Properties of Natural Products Through the Expression of Heme Oxygenase-1
Mini-Reviews in Organic Chemistry Beta Blocker Use After Acute Myocardial Infarction in the Patient with Normal Systolic Function: When is it “Ok” to Discontinue?
Current Cardiology Reviews Propofol Pharmacokinetics in Patients with Obstructive Jaundice
Current Drug Delivery Potential Role of microRNAs in Cardiovascular Disease: Are They up to Their Hype?
Current Cardiology Reviews Neuronal Regulators and Vascular Dysfunction in Raynauds Phenomenon and Systemic Sclerosis
Current Vascular Pharmacology Disease-Induced Neuroinflammation and Depression
CNS & Neurological Disorders - Drug Targets New Frontiers in the Management of Acute Coronary Syndromes: Cangrelor and Elinogrel
Recent Patents on Cardiovascular Drug Discovery Hepatocarcinogenesis and Ceramide/Cholesterol Metabolism
Anti-Cancer Agents in Medicinal Chemistry The Multifunctional Protein C System
Current Medicinal Chemistry - Cardiovascular & Hematological Agents Simvastatin and Other HMG-CoA Reductase Inhibitors on Brain Cholesterol Levels in Alzheimers Disease
Current Alzheimer Research Toxics of Tobacco Smoke and Cardiovascular System: From Functional to Cellular Damage
Current Pharmaceutical Design Erythropoietin: New Approaches to Improved Molecular Designs and Therapeutic Alternatives
Current Pharmaceutical Design Potential Application of Biliverdin Reductase and its Fragments to Modulate insulin/IGF-1/MAPK/PI3-K Signaling Pathways in Therapeutic Settings
Current Drug Targets Potential of Flavonoids as Anti-inflammatory Agents: Modulation of Pro- Inflammatory Gene Expression and Signal Transduction Pathways
Current Drug Metabolism Modulation of Cell Death in Age-Related Diseases
Current Pharmaceutical Design